Tramadol

does it have a role in cancer pain management?

Eric E. Prommer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Tramadol (Ultram, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ) is considered a Step 2 analgesic under the World Health Organization's guidelines for the treatment of patients with cancer pain. It is a centrally acting analgesic that has affinity for opioid receptors and influences the action of norepinephrine and serotonin at the synapse. This dual mechanism of analgesia makes it unique among Step 2 agents. It is metabolized by CYP2D6, which increases the potentialfor drug interactions. Unlike other opioids, it does not cause respiratory depression. Tramadol has been studied in cancer pain and neuropathic pain. It compares well with low-dose morphine as an analgesic. The purpose of this review is to critically examine the pharmacodynamics, pharmacology, drug interactions, and adverse effects of the drug, and, based on the data presented, discuss the drug's role in cancer care.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalJournal of Opioid Management
Volume1
Issue number3
StatePublished - Jul 2005
Externally publishedYes

Fingerprint

Tramadol
Pain Management
Analgesics
Drug Interactions
Pharmaceutical Preparations
Cytochrome P-450 CYP2D6
Opioid Receptors
Neuralgia
Respiratory Insufficiency
Synapses
Analgesia
Morphine
Opioid Analgesics
Serotonin
Norepinephrine
Pharmacology
Guidelines
Cancer Pain
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Anesthesiology and Pain Medicine

Cite this

Tramadol : does it have a role in cancer pain management? / Prommer, Eric E.

In: Journal of Opioid Management, Vol. 1, No. 3, 07.2005, p. 131-138.

Research output: Contribution to journalArticle

Prommer, Eric E. / Tramadol : does it have a role in cancer pain management?. In: Journal of Opioid Management. 2005 ; Vol. 1, No. 3. pp. 131-138.
@article{0c1216fe7d104cc29278b4bbd8b9de63,
title = "Tramadol: does it have a role in cancer pain management?",
abstract = "Tramadol (Ultram, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ) is considered a Step 2 analgesic under the World Health Organization's guidelines for the treatment of patients with cancer pain. It is a centrally acting analgesic that has affinity for opioid receptors and influences the action of norepinephrine and serotonin at the synapse. This dual mechanism of analgesia makes it unique among Step 2 agents. It is metabolized by CYP2D6, which increases the potentialfor drug interactions. Unlike other opioids, it does not cause respiratory depression. Tramadol has been studied in cancer pain and neuropathic pain. It compares well with low-dose morphine as an analgesic. The purpose of this review is to critically examine the pharmacodynamics, pharmacology, drug interactions, and adverse effects of the drug, and, based on the data presented, discuss the drug's role in cancer care.",
author = "Prommer, {Eric E.}",
year = "2005",
month = "7",
language = "English (US)",
volume = "1",
pages = "131--138",
journal = "Journal of Opioid Management",
issn = "1551-7489",
publisher = "Weston Medical Publishing",
number = "3",

}

TY - JOUR

T1 - Tramadol

T2 - does it have a role in cancer pain management?

AU - Prommer, Eric E.

PY - 2005/7

Y1 - 2005/7

N2 - Tramadol (Ultram, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ) is considered a Step 2 analgesic under the World Health Organization's guidelines for the treatment of patients with cancer pain. It is a centrally acting analgesic that has affinity for opioid receptors and influences the action of norepinephrine and serotonin at the synapse. This dual mechanism of analgesia makes it unique among Step 2 agents. It is metabolized by CYP2D6, which increases the potentialfor drug interactions. Unlike other opioids, it does not cause respiratory depression. Tramadol has been studied in cancer pain and neuropathic pain. It compares well with low-dose morphine as an analgesic. The purpose of this review is to critically examine the pharmacodynamics, pharmacology, drug interactions, and adverse effects of the drug, and, based on the data presented, discuss the drug's role in cancer care.

AB - Tramadol (Ultram, Ortho-McNeil Pharmaceutical, Inc., Raritan, NJ) is considered a Step 2 analgesic under the World Health Organization's guidelines for the treatment of patients with cancer pain. It is a centrally acting analgesic that has affinity for opioid receptors and influences the action of norepinephrine and serotonin at the synapse. This dual mechanism of analgesia makes it unique among Step 2 agents. It is metabolized by CYP2D6, which increases the potentialfor drug interactions. Unlike other opioids, it does not cause respiratory depression. Tramadol has been studied in cancer pain and neuropathic pain. It compares well with low-dose morphine as an analgesic. The purpose of this review is to critically examine the pharmacodynamics, pharmacology, drug interactions, and adverse effects of the drug, and, based on the data presented, discuss the drug's role in cancer care.

UR - http://www.scopus.com/inward/record.url?scp=33947216858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947216858&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 131

EP - 138

JO - Journal of Opioid Management

JF - Journal of Opioid Management

SN - 1551-7489

IS - 3

ER -